Inhibition of epidermal growth factor receptor by erlotinib: Wound healing of experimental tympanic membrane perforations

Otology and Neurotology

Volumn 28, Issue 2, 2007, Pages 245-249

  Kaftan, Holger ^a   Vogelgesang, Silke ^a   Lempas, Kathrin ^a   Hosemann, Werner ^a   Herzog, Michael ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

EGFR; Erlotinib; Myringotomy; Tympanic membrane; Wound healing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EARDRUM PERFORATION; HISTOPATHOLOGY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; WOUND HEALING;

ANIMALS; CHRONIC DISEASE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYMPANIC MEMBRANE PERFORATION; WOUND HEALING;

EID: 33846581948     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/01.mao.0000244366.24449.db     Document Type: Article

References (22)

1. Kartush JM. Tympanic membrane patcher: a new device to close tympanic membrane perforations in an office setting. Am J Otol 2000;21:615-20.
2. Lee AJ, Jackler RK, Kato M, et al. Repair of chronic tympanic membrane perforations using epidermal growth factor: Progress toward clinical application. Am J Otol 1994;15:10-8.
3. Amoils CP, Jackler RK, Lustig LR. Repair of chronic tympanic membrane perforations using epidermal growth factor. Otolaryngol Head Neck Surg 1992;107:669-83.
4. Fina M, Baird A, Ryan A. Direct application of basic fibroblast growth factor improved tympanic membrane perforation healing. Laryngoscope 1993;103:804-9.
5. Amoils CP, Jackler RK, Milczuk H, et al. An animal model of chronic tympanic membrane perforation. Otolaryngol Head Neck Surg 1992;106:47-55.
6. Dvorak DW, Abbas G, Ali T, et al. Repair of chronic tympanic membrane perforations with long-term epidermal growth factor. Laryngoscope 1995;105:1300-4.
7. Spiegel JH, Kessler JL. Tympanic membrane perforation repair with acellular porcine submucosa. Otol Neurotol 2005;26: 563-6.
8. Schmidt SH, Hellstrom S. Tympanic membrane structure-new views: a comparative study. ORL J Otorhinolaryngol Relat Spec 1991;53:32-6.
9. Kaftan H, Hosemann W, Beule A, et al. An improved animal model for chronic perforation of the tympanic membrane. HNO 2004;52:714-9.
10. Gladstone HB, Jackler RK, Varav K. Tympanic membrane wound healing. Otolaryngol Clin North America 1995;28:913-32.
11. O'Daniel TG, Petitjean M, Jones SC, et al. Epidermal growth factor binding and action on tympanic membranes. Ann Otol Rhinol Laryngol 1990;99:80-4.
12. Somers T, Goovaerts G, Schelfhout L, et al. Growth factors in tympanic membrane perforations. Am J Otol 1998;19:428-34.
13. Yano S, Kondo K, Yamaguchi M, et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003;23:3639-50.
14. Perrone F, Di Maio M, Budillon A, et al. Targeted therapies and non-small cell lung cancer: Methodological and conceptual challenge for clinical trials. Curr Opin Oncol 2005;17:123-9.
15. Jassir D, Buchman CA, Gomez-Marin O. Safety and efficacy of topical mitomycin C in myringotomy patency. Otolaryngol Head Neck Surg 2001;124:368-73.
16. Kaftan H, Herzog M, Miehe B, et al. Topical application of transforming growth factor-β1 in acute traumatic tympanic membrane perforations: An experimental study in rats. Wound Repair Regen 2006;14:453-6.
17. Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): Role in corneal wound healing and homeostasis. Exp Eye Res 2001;72:511-7.
18. Hirata A, Ogawa S, Kometani T, et al. ZD 1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-60.
19. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptorYassociated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-48.
20. Repertinger SK, Campagnaro E, Fuhrman J, et al. EGFR enhances early healing after cutaneous incisional wounding. J Invest Dermatol 2004;123:982-9.
21. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79.
22. Govindan R, Behnken D, Read W, et al. Wound healing is not impaired by the epidermal growth factor receptorYtyrosine kinase inhibitor gefitinib. Ann Oncol 2003;14:1330-1.